November 13, 2013
The ability of biosimilars makers to make early challenges to biologic drug patents may be curtailed by a Tuesday ruling throwing out Sandoz Inc.'s suit to invalidate patents for Amgen Inc.'s biologic arthritis drug Enbrel, the first time a judge has interpreted the litigation provisions of the Biosimilars Act.
June 26, 2013
Amgen Inc. and Hoffman-La Roche Inc. were struck with a California federal lawsuit Tuesday from Sandoz Inc. that says a generic form of arthritis drug Enbrel is not infringing two patents and a delay in the patents' issuance renders them invalid.